Here are five key things to know:
1. The spinal cord injury repair drug, originally called Cethrin, is 15 years old.
2. The drug, now called VX-210, was abandoned during the financial crisis, but one of the innovating neuroscientists resurrected it.
3. Vertex paid just $10 million for the drug up front, and could pay around $90 million in the future as VX-210 goes into Phase 2b trial.
4. There is also a trigger that would allow Vertex to purchase BioAxone outright.
5. The drug seemed “off the radar” for some, but fits within Vertex’s neurological disease” platforms. The initial acquisition was low-risk for Vertex.
More articles on orthopedic devices:
LDR’s 4Q revenue up 23.6%: 12 key notes
10 key notes on Exactech’s 2014
4 key points on global sports medicine devices market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
